NCT00996723已完成1 期
Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- To estimate the maximum tolerated dose (MTD) of the combination of vandetanib and dasatinib administered concurrently with RT in pediatric research participants with newly diagnosed DIPG
研究概览
简要总结
This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
详细描述
This trial will estimate the maximum safe dose of vandetanib and dasatinib which can be administered during the 6 weeks of local RT in children with newly diagnosed DIPG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Months 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age must be ≥ 18 months and < 21 years
- •Diagnosis of DIPG or high-grade glioma originating from the brainstem.
- •Lansky (for research participants ≤ 16 years) or Karnofsky (for research participants > 16 years) performance score ≥ 40 at the time of study enrollment
- •Adequate organ function at the time of study enrollment as follows:
- •Bone marrow: ANC ≥ 1,000/μL, platelet count ≥ 100,000/μL (transfusion independent), hemoglobin concentration ≥ 8g/dL (may be transfused)
- •Renal: Serum creatinine concentration < 2x the institutional normal values for age or GFR > 70ml/min/1.73m2
- •Hepatic: Total bilirubin concentration < 1.5x the institutional upper limit of normal for age; SGPT < 5x the institutional upper limit of normal; albumin ≥ 2 g/dL
- •Electrocardiogram (EKG) with an average QTc interval < 450 msec. If a research participant has QTc interval ≥ 450 msec on screening EKG, the screening EKG may be repeated twice (at least 24 hours apart). The average QTc interval from the three screening EKGs must be < 450 msec in order for the research participant to be eligible for the study. Research participants with abnormal serum electrolytes and a QTc interval ≥ 450 msec should have a repeat EKG repeated once the concentration of serum electrolyte is corrected
- •Female research participants of childbearing age must not be pregnant (confirmed by serum or urine pregnancy test within 1 week of treatment start) or breast-feeding.
- •Female research participants of childbearing age and male research participants of child fathering potential must agree to use safe contraceptive methods
排除标准
- •Metastatic disease
- •Use of enzyme-inducing anticonvulsants
- •Research participants who received any other type of anticancer treatment
- •Research participants with uncontrolled infection
- •Research participants with any concomitant significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy, or that would impair the evaluation of side effects related to this treatment, alter drug metabolism or the tolerance to this treatment
- •QTc interval prolongation with other medications that required discontinuation of that medication
- •Research participants with any history of cardiac arrhythmias or congenital long QT syndrome
- •Use of any concomitant medication that may cause QT interval prolongation and/or induce Torsades de Pointes
- •Hypertension defined as systolic and/or diastolic blood pressure > 95th percentile for age, height and gender, or blood pressure > 140/90 for research participants ≥ 18 years of age. If hypertension is detected, blood pressure values < 95th in two separate occasions need to be documented before registration. Body surface ≥ 1.8m2 for research participants enrolled on dosage levels 2, 3, and 4
研究组 & 干预措施
1
Other
干预措施: vandetanib and dasatinib (Drug)
结局指标
主要结局
To estimate the maximum tolerated dose (MTD) of the combination of vandetanib and dasatinib administered concurrently with RT in pediatric research participants with newly diagnosed DIPG
时间窗: April 2012
次要结局
- To evaluate the influence of specific polymorphisms (e.g., CYP3A4/5) on the pharmacokinetics of vandetanib and dasatinib administered in combination(July 2012)
- To describe the research participants' and parents' perspective of the quality of life of children with newly diagnosed DIPG enrolled on this phase I trial(July 2012)
- To describe the quality of life of parents of pediatric research participants with newly diagnosed DIPG enrolled on this phase I trial(July 2012)
- To determine the toxicities associated with the chronic use of vandetanib and dasatinib(July 2012)
- To explore the association between plasma angiogenic factors and response to current therapy(July 2012)
- To characterize the pharmacokinetics of vandetanib and dasatinib in pediatric research participants(July 2012)
- To evaluate the pharmacodynamics of dasatinib in target receptors and pathways in peripheral mononuclear cells(July 2012)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaNCT01876953City of Hope Medical Center20
已完成
1 期
Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem GliomaBrain and Central Nervous System TumorsNCT00472017St. Jude Children's Research Hospital35
已完成
1 期
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerAdvanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant NeoplasmRefractory Malignant NeoplasmNCT01582191M.D. Anderson Cancer Center123
已完成
1 期
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)Non Small Cell Lung CancerCancerNCT01586624Cancer Research UK61
撤回
1 期
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and ParagangliomaPhaeochromocytomaParagangliomaNCT01941849University College, London